Compare UBC Medical Indonesia Tbk. (LABS) vs Adiwarna Anugerah Abadi Tbk. (NAIK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
UBC Medical Indonesia Tbk. vs Adiwarna Anugerah Abadi Tbk. — how do they compare? UBC Medical Indonesia Tbk. trades at Rp168 (market cap 651.75B, 848.2K 24h volume), while Adiwarna Anugerah Abadi Tbk. trades at Rp89 (market cap 296.32B, 1.44M 24h volume). The key difference: UBC Medical Indonesia Tbk. is far larger — about 2.2× Adiwarna Anugerah Abadi Tbk.'s market cap, and Adiwarna Anugerah Abadi Tbk. is more actively traded (1.44M versus 848.2K). Which is the better fit depends on your goals.
| LABS | NAIK | |
|---|---|---|
Market Cap | 651.75B | 296.32B |
Volume | 848.2K | 1.44M |
Lot | 8.48K | 14.44K |
Turnover | 140.51M | 127.24M |
Average Price | 165.66 | 88.14 |
Value | 140.51M | 127.24M |
Indicative Equilibrium Price | 168 | 89 |
Indicative Equilibrium Volume | 50 | 80 |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About UBC Medical Indonesia Tbk.
PT UBC Medical Indonesia (the Company) was established under the framework of Law of the Republic of Indonesia No. 20 year 1994 concerning the Foreign Capital Investment, as amended by Law No. 25 year 2007 concerning the Capital Investment based on Notarial Deed No. 01 dated 4 June 2014 of Novita Puspitarini, S.H., Notary in Jakarta. The Company started its commercial activities in October 2014. The parent entity as well as the ultimate parent entity of the Company is PT Optel Investama Mulia.
Read more on LABS →About Adiwarna Anugerah Abadi Tbk.
PT Adiwarna Anugerah Abadi Tbk was established based on Deed of notary Rony Saputra Sudarmo, SH., No.4 dated 8 May 2007. The Company started its commercial operations in 2007. The Company parent entity is PT Adiwarna Anugerah Investama. Mr. Johannes and Mrs. Ernawati is the final controller of the Company.
Read more on NAIK →
